BACKGROUND: There are limited data measuring the impact of expanded human immunodeficiency virus (HIV) prevention activities on the tuberculosis epidemic at the country level. Here, we characterized the potential impact of the US President's Emergency Plan for AIDS Relief (PEPFAR) on the tuberculosis epidemic in sub-Saharan Africa. METHODS: We selected 12 focus countries (countries receiving the greatest US government investments) and 29 nonfocus countries (controls). We used tuberculosis incidence and mortality rates and relative risks to compare time periods before and after PEPFAR's inception, and a tuberculosis/HIV indicator to calculate the rate of change in tuberculosis incidence relative to the HIV prevalence. RESULTS: Comparing the periods before and after PEPFAR's implementation, both tuberculosis incidence and mortality rates have diminished significantly and to a higher degree in focus countries. The relative risk for developing tuberculosis, comparing those with and without HIV, was 22.5 for control and 20.0 for focus countries. In most focus countries, the tuberculosis epidemic is slowing down despite some regions still experiencing an increase in HIV prevalence. CONCLUSIONS: This ecological study showed that PEPFAR had a more consistent and substantial effect on HIV and tuberculosis in focus countries, highlighting the likely link between high levels of HIV investment and broader effects on related diseases such as tuberculosis.
BACKGROUND: There are limited data measuring the impact of expanded human immunodeficiency virus (HIV) prevention activities on the tuberculosis epidemic at the country level. Here, we characterized the potential impact of the US President's Emergency Plan for AIDS Relief (PEPFAR) on the tuberculosis epidemic in sub-Saharan Africa. METHODS: We selected 12 focus countries (countries receiving the greatest US government investments) and 29 nonfocus countries (controls). We used tuberculosis incidence and mortality rates and relative risks to compare time periods before and after PEPFAR's inception, and a tuberculosis/HIV indicator to calculate the rate of change in tuberculosis incidence relative to the HIV prevalence. RESULTS: Comparing the periods before and after PEPFAR's implementation, both tuberculosis incidence and mortality rates have diminished significantly and to a higher degree in focus countries. The relative risk for developing tuberculosis, comparing those with and without HIV, was 22.5 for control and 20.0 for focus countries. In most focus countries, the tuberculosis epidemic is slowing down despite some regions still experiencing an increase in HIV prevalence. CONCLUSIONS: This ecological study showed that PEPFAR had a more consistent and substantial effect on HIV and tuberculosis in focus countries, highlighting the likely link between high levels of HIV investment and broader effects on related diseases such as tuberculosis.
Authors: Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye Journal: Proc Natl Acad Sci U S A Date: 2010-10-25 Impact factor: 11.205
Authors: Anthony D Harries; Rony Zachariah; Elizabeth L Corbett; Stephen D Lawn; Ezio T Santos-Filho; Rhehab Chimzizi; Mark Harrington; Dermot Maher; Brian G Williams; Kevin M De Cock Journal: Lancet Date: 2010-05-18 Impact factor: 79.321
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Reuben Granich; Siobhan Crowley; Marco Vitoria; Ying-Ru Lo; Yves Souteyrand; Christopher Dye; Charlie Gilks; Teguest Guerma; Kevin M De Cock; Brian Williams Journal: J Int AIDS Soc Date: 2010-01-12 Impact factor: 5.396
Authors: Amitabh B Suthar; Stephen D Lawn; Julia del Amo; Haileyesus Getahun; Christopher Dye; Delphine Sculier; Timothy R Sterling; Richard E Chaisson; Brian G Williams; Anthony D Harries; Reuben M Granich Journal: PLoS Med Date: 2012-07-24 Impact factor: 11.069
Authors: Helen L Zhang; Michael W Omondi; Augustine M Musyoka; Isaac A Afwamba; Remigi P Swai; Francis P Karia; Charles Muiruri; Elizabeth A Reddy; John A Crump; Matthew P Rubach Journal: Am J Clin Pathol Date: 2016-08 Impact factor: 2.493
Authors: Enju Liu; Abel Makubi; Paul Drain; Donna Spiegelman; David Sando; Nan Li; Guerino Chalamilla; Christopher R Sudfeld; Ellen Hertzmark; Wafaie W Fawzi Journal: AIDS Date: 2015-07-17 Impact factor: 4.177
Authors: Aishatu Lawal Adamu; Muktar H Aliyu; Najiba Aliyu Galadanci; Baba Maiyaki Musa; Umar Muhammad Lawan; Usman Bashir; Ibrahim Abubakar Journal: Int J Equity Health Date: 2018-01-08
Authors: Dale A Barnhart; Isaac Tsikhutsu; Duncan Kirui; Fredrick Sawe; Jane Muli; William Sugut; Nareen Abboud; Deborah Birx; Tiffany Hamm; Peter Coakley; Patrick W Hickey; Vanessa Wolfman; Elizabeth Lee; Donna Spiegelman Journal: JAMA Netw Open Date: 2019-09-04
Authors: Jessica B McGillen; Alana Sharp; Brian Honermann; Gregorio Millett; Chris Collins; Timothy B Hallett Journal: AIDS Date: 2017-11-28 Impact factor: 4.177